Cancers can make themselves harder for new immunotherapies to see by ‘changing their spots’ – and switching off a key molecule on the surface of cells that is otherwise recognised by treatment.

Researchers at the ICR show that triple drug combinations could prevent resistance in many cancer types.

Scientists have identified a protein which is associated with more aggressive breast, colorectal and ovarian cancers, which could be used to assist the diagnosis and development treatments for these cancers.